Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Kuros Biosciences AG    KURN   CH0325814116

KUROS BIOSCIENCES AG

(KURN)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
2.98(c) 2.97(c) 2.97(c) 2.9(c) 2.9(c) Last
22 505 13 674 33 732 26 881 26 517 Volume
0.00% -0.34% 0.00% -2.36% 0.00% Change
More quotes
Financials (CHF)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 -
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 -
Capi. / Sales2020 -
Capitalization 65,1 M
More Financials
Company
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension,... 
More about the company
Latest news on KUROS BIOSCIENCES AG
01/30Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superior..
GL
2019Page and Brin let Google go, and other companies’ news
2019Kuros announces final result of Capital Increase – total gross proceeds..
TE
2019Kuros announces results of Rights Offering
TE
2019Kuros provides an update on the Capital Increase
TE
2019KUROS BIOSCIENCES AG : RIGHTS ISSUE: 2 new shares @ 1.95 CHF for 5 existing shar..
FA
2019Extraordinary General Meeting of Kuros Biosciences approves all resolutions
TE
2019Kuros announces the terms of the proposed capital increase through a discount..
TE
2019Kuros convenes Extraordinary General Meeting
TE
2019Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its..
GL
2019KUROS BIOSCIENCES : announces full commercial launch of MagnetOs™ and exhi..
PU
2019Kuros Biosciences announces full commercial launch of MagnetOs™ and exh..
GL
2019Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate ..
GL
2019Kuros Biosciences Reports Results for First Half 2019
TE
2019Kuros announces Gerhard Ries is stepping down as Board member
TE
More news
News in other languages on KUROS BIOSCIENCES AG
01/30Kuros legt positive Daten zu MagnetOS vor
01/10KUROS-CEO : Wir haben Kuros zu einen fokussierten Knochenspezialisten gemacht
2019Kuros lève 12,5 millions grâce à l'augmentation de capital
2019Kuros nimmt über Kapitalerhöhung insgesamt 12,5 Mio Fr. ein
2019KUROS : les actuels actionnaires ont souscrit 36% de l'augmentation de capital
More news
Sector news : Bio Therapeutic Drugs
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Therapeutic Drugs
Chart KUROS BIOSCIENCES AG
Duration : Period :
Kuros Biosciences AG Technical Analysis Chart | KURN | CH0325814116 | MarketScreener
Technical analysis trends KUROS BIOSCIENCES AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 2,90  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Joost D. de Bruijn Chief Executive Officer & Director
Clemens A. van Blitterswijk Chairman
Michael Grau Chief Financial Officer
Pascal Longlade Chief Medical Officer
Leanna Caron Director
Sector and Competitors
1st jan.Capitalization (M$)
KUROS BIOSCIENCES AG18.37%67
GILEAD SCIENCES3.11%88 181
VERTEX PHARMACEUTICALS12.49%63 855
REGENERON PHARMACEUTICALS6.30%43 886
WUXI APPTEC CO., LTD.22.35%26 379
GENMAB A/S14.61%16 125